NCT00400621已完成4 期
Assessment of Hepatic Injury in Subjects Who Consume Moderate Amounts of Alcohol While Being Administered Therapeutic Doses of Acetaminophen:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 150
- 主要终点
- mean change in serum ALT between treatment groups
研究概览
简要总结
The study objective was to evaluate the safety of ten consecutive days of therapeutic acetaminophen dosing in moderate alcohol consumers. The main outcome was liver injury (measured by an increase in mean serum ALT or AST levels). Patients were randomly assigned to 10 days of acetaminophen or placebo. Blood tests were measured at baseline, day 4 and day 11 to look for injury. We hypothesized that there would be no difference in liver enzymes between the two groups.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult volunteers of age 21 years or older, regardless of ethnicity or gender, who provided written consent and met all three of the following criteria of a moderate alcohol consumer:
- •Average baseline ethanol consumption of at least one alcoholic beverage per day before enrollment for the past two months. The estimate of ethanol intake was based on the average intake over seven days. For example, a person who ingested no alcohol on Sunday, Monday, Tuesday or Wednesday, two drinks on Thursday and four drinks on Friday and Saturday would be calculated as 10 drinks/7days = 1.4 drinks/day. The average alcoholic beverage contains 15 grams of alcohol(9).
- •Average baseline ethanol consumption of no more than three alcoholic beverages (> 45 grams of alcohol) per day, calculated as a weekly average over the preceding two months.
- •At least one alcohol-containing drink within the last 48 hours
排除标准
- •Subjects were excluded from the study at baseline if any of the following were evident at baseline:
- •Serum acetaminophen level greater than 20 mcg/ml
- •Serum AST or ALT levels greater than 50 IU/L
- •If female, positive for b-HCG
- •Clinically intoxicated, psychiatrically impaired or unable to give informed consent
- •Known hypersensitivity to acetaminophen
- •History of ingesting more than four grams of acetaminophen per day for any of the four days preceding study enrollment
- •Alcoholic patients as defined by those who consume on average more than three alcoholic beverages daily
- •Currently enrolled in another trial or had been enrolled in another trial in the preceding three months
结局指标
主要结局
mean change in serum ALT between treatment groups
次要结局
- proportion of patients that developed an abnormal ALT
- proportion of patients that developed hepatoxicity (ALT>1000 IU>L)
- proportion of patients that developed drug induced liver injury
研究者
相似试验
已完成
不适用
Acetaminophen-induced Hepatotoxicity in Chronic Alcohol AbusersHepatotoxicityNCT00137059Dr. Marco L.A. Sivilotti40
已完成
3 期
A Safety and Effectiveness Study of Acetaminophen (4000 mg/Day) and Naproxen (750 mg/Day) in the Treatment of Osteoarthritis of the Hip or KneeOsteoarthritis, HipOsteoarthritis, KneeNCT00240773Johnson & Johnson Consumer and Personal Products Worldwide581
已完成
1 期
Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric InpatientsPainFeverNCT00493246Mallinckrodt75
已完成
不适用
Treatment of Acetaminophen Toxicity With N-acetylcysteineAcetaminophen ToxicityNCT00725179Akron Children's Hospital130
已完成
4 期
A Safety and Effectiveness Study of Acetaminophen Extended Release (3900 mg/Day) and Ibuprofen (1200 mg/Day) in the Treatment of Pain Associated With Ankle Sprains.Sprains and StrainsPainNCT00261560Johnson & Johnson Consumer and Personal Products Worldwide260